AIDSVAX results: an important open question
Апстракт
Research and clinical data reported during last 10 years indicate the possibility that AIDS vaccines based on the HIV-1 envelope protein gp120 may be worse then useless. A correct assessment of the safety of these AIDS vaccines can not be possible without data which will allow comparison of the disease status between breakthrough HIV infected vaccinated volunteers and those from the control group. Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis. (C) 2003 Elsevier Science Ltd. All rights reserved.
Кључне речи:
AIDSVAX / population explosion / AIDSИзвор:
Vaccine, 2003, 21, 25-26, 3528-3529
DOI: 10.1016/S0264-410X(03)00324-4
ISSN: 0264-410X
PubMed: 12922078
WoS: 000185233700004
Scopus: 2-s2.0-0242349141
Колекције
Институција/група
VinčaTY - JOUR AU - Veljković, Veljko AU - Muller, S AU - Kohler, Heike PY - 2003 UR - https://vinar.vin.bg.ac.rs/handle/123456789/2665 AB - Research and clinical data reported during last 10 years indicate the possibility that AIDS vaccines based on the HIV-1 envelope protein gp120 may be worse then useless. A correct assessment of the safety of these AIDS vaccines can not be possible without data which will allow comparison of the disease status between breakthrough HIV infected vaccinated volunteers and those from the control group. Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis. (C) 2003 Elsevier Science Ltd. All rights reserved. T2 - Vaccine T1 - AIDSVAX results: an important open question VL - 21 IS - 25-26 SP - 3528 EP - 3529 DO - 10.1016/S0264-410X(03)00324-4 ER -
@article{ author = "Veljković, Veljko and Muller, S and Kohler, Heike", year = "2003", abstract = "Research and clinical data reported during last 10 years indicate the possibility that AIDS vaccines based on the HIV-1 envelope protein gp120 may be worse then useless. A correct assessment of the safety of these AIDS vaccines can not be possible without data which will allow comparison of the disease status between breakthrough HIV infected vaccinated volunteers and those from the control group. Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis. (C) 2003 Elsevier Science Ltd. All rights reserved.", journal = "Vaccine", title = "AIDSVAX results: an important open question", volume = "21", number = "25-26", pages = "3528-3529", doi = "10.1016/S0264-410X(03)00324-4" }
Veljković, V., Muller, S.,& Kohler, H.. (2003). AIDSVAX results: an important open question. in Vaccine, 21(25-26), 3528-3529. https://doi.org/10.1016/S0264-410X(03)00324-4
Veljković V, Muller S, Kohler H. AIDSVAX results: an important open question. in Vaccine. 2003;21(25-26):3528-3529. doi:10.1016/S0264-410X(03)00324-4 .
Veljković, Veljko, Muller, S, Kohler, Heike, "AIDSVAX results: an important open question" in Vaccine, 21, no. 25-26 (2003):3528-3529, https://doi.org/10.1016/S0264-410X(03)00324-4 . .